An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to Parma.
Guests, which included Vice Minister of Business and Made in Italy, Valentino Valentini, joined to celebrate the start of the work on the building, the new Italian and international center of excellence to produce biologic drugs.
Expected to open and be fully operational in 2024, the center will specialize in the development and production of the active ingredients of monoclonal antibodies (produced through recombinant DNA techniques starting from a single type of immune cell), enzymes and other proteins.
Chiesi focusing on biological drugs
“The success of Made in Italy is possible thanks to realities such as Chiesi, in first place among private companies for investment in research and development in Italy: over 20% of turnover, around half a billion Euro in 2022, and in first place for the number of patents.
“The Chiesi Group is now focusing on biological drugs including monoclonal antibodies with an 85 million Euro investment in an international center of excellence in Parma,
The post Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
This content was originally published here.
